New Ruipeng Pet Healthcare Group

1.1 Identity, footprint, and operating scope

New Ruipeng is best understood as three corporate layers rather than one simple founding date. The operating origin traces back to December 1998, when Peng Yonghe founded Ruipeng Pet Hospital in Shenzhen. Baidu's company profile treats 26 November 2013 as the establishment date of the group legal entity now profiled as New Ruipeng Pet Healthcare Group. The current structure was then reshaped in 2018, when Ruipeng completed strategic cooperation with Hillhouse and began operating under the broader New Ruipeng platform. Finally, the Cayman holding company used for the U.S. listing attempt was incorporated in June 2019. Using all three dates avoids a common mistake: calling the business either a 1998 startup or a 2019 Cayman shell without clarifying that both statements refer to different layers of the same platform. The operating scope is also broader than a plain veterinary chain. The company and filing both describe three main pillars — pet care services, supply chain services, and local services — while the official site adds diagnostics, internet tools, welfare programs, talent development, and other adjacent functions. The current English-language website highlights more than 20 brands, more than 1,000 hospitals, and more than 90 cities. The last SEC-era disclosures were even larger: 23 brands, 1,891 hospitals, 113 cities, and operations in 31 provinces at 2022 year-end, rising to 1,942 hospitals and 114 cities by September 2022 in IPO marketing materials. The precise current audited hospital count is therefore unclear, but the combined sources leave no doubt that New Ruipeng remains the largest scaled pet-hospital network publicly documented in China.[CO001, CO002, CO003, CO004, CO005, CO006]

1.2 Leadership, governance, and control

Peng Yonghe remains the central human anchor of the company. The F-1/A identifies him as founder, co-chairman, and president, and his biography runs continuously through the Ruipeng operating history from veterinarian to entrepreneur. However, the governance design disclosed for the IPO shows that New Ruipeng is not founder-controlled in the simple sense often associated with private roll-ups. Under the September 2020 shareholder agreement, management appointees had four board seats and Hillhouse-linked entities had four more, while Dachen and Riverhead each had one. That split implies strong investor oversight over capital allocation and governance even before any public listing. The rest of the disclosed leadership bench is meaningful but still concentrated. Liang Li brought Hillhouse directly into the chairmanship as co-chairman and partner. Yanzhong Zhang represents long-tenured operating continuity from the legacy Ruipeng system and now shows up in official 2025 communications as the hospital-group general manager. Chenguang Zhou brought listed-company finance experience from China Foods and COFCO-linked roles. Even so, reviewed public materials still concentrate strategic legitimacy in Peng. There is no post-withdrawal public disclosure of a refreshed board charter, a new independent governance framework, or a succession plan after the failed IPO process. For a company this large, the governance picture is therefore adequate for understanding ownership influence but still incomplete for underwriting long-term execution depth.[CO010, CO011, CO012, CO013, CO014, CO015]

1.3 Capital history and disclosure quality

The best-documented external capital event remains the September-October 2020 financing disclosed in the F-1/A. That filing names Tencent, Boehringer Ingelheim, Snow Lake, Gracious Rhythm, Worldwide Healthcare Trust, OrbiMed funds, Aspex, LBC, AIG, and ABCI, for roughly US$558 million of Class B capital across several tranches. Independent coverage by Global Venturing and KrASIA described the broader round as a Tencent-led raise worth hundreds of millions and attached a roughly US$4.4 billion valuation. In January 2023, just before the IPO push, New Ruipeng also issued a US$50 million convertible note to a Nestlé subsidiary. Importantly, Petfoodie's contemporaneous coverage said the amount and valuation were not publicly disclosed in press materials, so investors still rely on the SEC filing for the exact note size. Disclosure quality is the central limitation of the overview. The IPO filing gives a surprisingly rich 2022 picture — RMB5.74 billion of revenue, RMB318.8 million gross profit, RMB1.42 billion net loss, negative RMB948.2 million adjusted EBITDA, RMB566.8 million cash, 2.6 million active pet-care customers, and 5.2 million Rvet registered users. After the June 2024 withdrawal, however, the company returned to a more selective disclosure stance. Official 2025 news provides operating signals such as a claimed March 2025 profitability turning point in the medical module, but no audited 2024 or 2025 financial statements were found in reviewed public materials. That means the company is still sizeable and well capitalized by historical standards, but investors no longer have a current public financial baseline.[CO016, CO017, CO018, CO019, CO020, CO021]

1.4 Milestones, strategic signals, and adverse developments

Recent public signals show a company that is still expanding its institutional role in China's pet-health ecosystem even while staying private. Official 2025 coverage emphasizes tighter cooperation with Meituan, standard-setting work with the Futian district government, and leadership in the first national guidance specific to pet diagnosis and treatment service institutions. The diagnostics and technology pages reinforce a strategy that pairs hospital scale with central labs, digital workflows, and specialty-care standardization. Business Wire China's Boehringer release adds another strategic layer: New Ruipeng is positioned not only as a veterinary-service chain but also as a partner for disease understanding, professional training, and broader animal-health distribution. The main adverse corporate milestone is the June 2024 withdrawal of the Nasdaq listing. The SEC letter is explicit that the company chose not to proceed, that the filing never became effective, and that no securities were sold. Renaissance Capital and IPOScoop both treated the transaction as a shelved US$100 million IPO. Since then, the public evidence reviewed here shows no replacement filing or firm relisting timetable. At the same time, Baidu's company profile says the business remained on the 2025 and 2026 Hurun global unicorn lists at RMB33 billion and RMB30.5 billion valuations respectively, suggesting that private-market status did not erase its unicorn standing. The combination matters: New Ruipeng still looks strategically important and operationally large, but its investability story is now driven more by historic scale and ecosystem position than by fresh public disclosure.[CO027, CO028, CO029, CO031, CO032, CO033]

1.5 Exhibits

2.1 Market boundary and what should count as TAM

The first analytical challenge is definitional. Some sources use “pet market” to mean the entire spending universe across food, supplies, services, and healthcare. Others use “pet care market” to mean a narrower services-heavy category centered on veterinary treatment and related care. Still others — especially healthcare research publishers — isolate pet-healthcare products and clinical-adjacent categories into a much smaller addressable market. For New Ruipeng, the right market boundary is not the full pet economy. The company monetizes a service-led mix built around hospitals, diagnostics, grooming, local services, and supply chain. That means total pet-economy numbers are useful for directional growth, but not as the valuation denominator. This distinction matters because the numbers diverge widely. Frost & Sullivan data reproduced in the F-1/A puts the total China pet market at RMB285.9 billion in 2022 and the narrower pet-care market at RMB56.3 billion. The 2026 white paper, by contrast, says urban dog-and-cat consumption reached RMB312.6 billion in 2025. StrategyHelix presents an even smaller future market of USD942.8 million by 2031 for “pet healthcare,” which is almost certainly a narrower product or healthcare category rather than the full veterinary-services opportunity. The correct takeaway is not that one of these sources is wrong; it is that they answer different questions. Later valuation work should therefore use layered TAM logic rather than a single headline market number.[CM001, CM002, CM003, CM004, CM005, CM006]

2.2 Buyer, user, payer, and demand formation

The economic buyer in pet healthcare is usually the pet owner, while the end user is the pet and the effective gatekeeper is the veterinarian or clinic brand that earns trust at the moment of care. China’s demand base is getting both larger and younger. The 2026 white paper says urban dog and cat population reached 126 million in 2025, while post-90s and post-00s owners represented roughly 69% of the market combined. These cohorts are digitally native, research-heavy, and increasingly willing to treat pets as long-duration household members instead of low-cost companions. Demand quality is rising even where raw pet-population growth is slower. Annual spend per dog and cat reached RMB3,006 and RMB2,085 in 2025, and hospital-visit rates increased for both species. Owners most often consult veterinarians or visit hospitals directly when dealing with disease questions, which means clinical trust remains the primary conversion mechanism even in a digital market. Adjacent service preferences also reinforce the importance of standardization: professional quality, proximity to home, and a clean environment rank highly in grooming and boarding decisions. That logic likely transfers into clinic choice as chains compete with independents. For New Ruipeng, this creates a favorable setup for a brand-and-network model rather than a pure online marketplace model.[CM008, CM009, CM010, CM011, CM012, CM013]

2.3 Growth drivers versus structural constraints

The market’s headline growth drivers are clear: low household pet ownership versus the U.S., lower per-pet spending than mature markets, younger urban owners, rising interest in preventive care, and the ability to cross-sell products and services once a pet owner enters a trusted network. The company’s own filing argues that 38% of hospital customers already consumed through other channels by 2022, illustrating the wallet-share upside once a chain captures the first medical interaction. In mature markets, Banfield and VCA show that large veterinary platforms can layer diagnostics, wellness plans, urgent care, and acquisition-led expansion on top of a wide base of neighborhood hospitals. The constraints are just as important. China’s industry remains fragmented and increasingly competitive. Licensing rules apply at both institution and practitioner level, and regulations around quarantine, waste disposal, disease reporting, veterinary drugs, and prescribed scope of practice make quality chains harder to scale than low-regulation retail concepts. Talent is the other bottleneck: hospital growth needs trained clinicians and specialty capacity, not just leases and marketing. That is why New Ruipeng’s emphasis on talent development and national standard setting matters strategically. Formalization raises the bar for everyone, but the operators with training systems, capital, and compliance infrastructure should gain relative advantage over smaller clinics.[CM014, CM015, CM026, CM027, CM028, CM029]

2.4 Market verdict for New Ruipeng

The best market judgment is constructive but not simplistic. China’s pet economy is unquestionably large, and its veterinary-service demand still looks underpenetrated relative to mature countries. However, the investable market for New Ruipeng is narrower than the most aggressive headline TAMs suggest. A realistic service TAM should sit somewhere between the filing’s pet-care market framing and broader service-share estimates, not at the full pet-economy level. That still leaves a large opportunity set for a scaled operator, because the combination of rising clinical demand, digital discovery, regulatory formalization, and fragmented local supply favors chains that can standardize care and absorb compliance costs. The unresolved issue is capture, not existence. Demand is present. The harder question is how much of that demand can be profitably served by licensed, quality-controlled, multi-brand hospital networks rather than by independent clinics, local platforms, and lower-cost informal providers. That is why later chapters must connect the attractive market backdrop to product execution, customer durability, and capital intensity before treating the market alone as an investment case.[CM018, CM019, CM020, CM034, CM036, CM037]

2.5 Exhibits

3.1 Landscape: who actually competes with New Ruipeng

The competitive map is broader than “New Ruipeng versus another hospital chain.” China’s pet-medical market remains fragmented, with the top five players representing only 15.4% of revenue in 2024 and single-entity hospitals still the mainstream format. That means New Ruipeng competes simultaneously against direct scaled chains, thousands of local independents, internet platforms that influence discovery and bookings, and international veterinary-service models that shape investor expectations. The company’s own structure also matters: New Ruipeng is not merely a clinic roll-up, but a platform spanning pet care, supply chain, and local services. Any realistic competitive assessment has to judge that platform breadth, not just raw hospital count. Ringpai is the clearest direct national rival because it has disclosed a multi-city hospital network, an acquisition program, outside capital, and an IPO-quality narrative about standardization and profitability. But the larger strategic threat may come from the combination of fragmented offline supply and platformized online demand. Pet owners can still multi-home across local clinics, and discovery increasingly flows through Meituan, JD, Baidu, and proprietary apps such as RVET. In other words, New Ruipeng’s biggest challenge is not only whether another chain can match its footprint; it is whether rivals or platforms can intercept the customer relationship before the chain’s scale advantages convert into repeat spend.[CP001, CP002, CP008, CP025, CP026, CP031]

3.2 Direct domestic rivals and the status-quo alternative

Ringpai is large enough to matter, but still small enough to leave New Ruipeng meaningfully ahead on disclosed scale. Pet Fair Asia and NewTimeSpace both describe Ringpai as operating 548 hospitals across roughly 70 cities by mid-2025, compared with New Ruipeng’s 1,891-hospital disclosure at 2022 year-end. The challenge for New Ruipeng is that Ringpai’s operating story may be cleaner. Independent reporting credits Ringpai’s VDP model with better retention of medical teams and a more controlled acquisition style, while criticizing New Ruipeng’s earlier full-buyout approach for heavy integration costs and internal competition. That does not make Ringpai dominant, but it does make it the most credible “better-executed number two.” The more stubborn rival remains the status quo: local clinics. Chain penetration around 22% means many pet owners still solve care needs through nearby independents that can be cheaper, more personal, or simply more convenient. This keeps switching costs low and makes brand moat difficult to enforce city by city. New Ruipeng’s answer is standardization and referral depth through a multi-brand network and 1+P+C structure, but those advantages only matter if customers perceive the quality gap and if doctors stay within the system.[CP003, CP004, CP006, CP020, CP021, CP025]

3.3 International incumbents and adjacent platform competitors

International comparators help show what a durable veterinary-service moat can look like. Banfield emphasizes preventive care, wellness plans, tele-advice, and life-stage care at very large national scale, while VCA combines primary, specialty, emergency, urgent care, and oncology with an acquisition playbook that preserves local-hospital identity. CVS Group offers a public-market lens for how investors value a listed veterinary chain. These examples matter because they suggest the end-state model for scaled veterinary care is not “more clinics” by itself, but a system that layers recurring programs, specialized services, standardized records, and trusted referral pathways. Adjacent digital platforms matter for a different reason: they can weaken the direct relationship between hospital chain and pet owner. JD’s 2026 partnership with New Ruipeng reaches into internet hospitals, insurance, diagnostics, and AI models; Meituan drives local bookings and group-buying; Baidu and JD previously cooperated on pet-doctor services; and RVET itself tries to keep discovery, consultation, booking, and follow-up inside New Ruipeng’s software surface. These platforms are not full substitutes for hospital delivery, but they are highly relevant competitors and partners because they mediate traffic, pricing visibility, and re-engagement.[CP009, CP010, CP011, CP012, CP013, CP014]

3.4 Moat durability and competitive verdict

The net competitive verdict is positive but not complacent. New Ruipeng still benefits from unmatched disclosed footprint, portfolio breadth, partner relationships, and a platform architecture that reaches beyond clinic revenue into supply chain and local services. Yet the moat is operational rather than unassailable. The Boehringer relationship is helpful, but not exclusive. JD and Meituan improve distribution but also create channel dependence. Ringpai’s VDP narrative shows a rival can plausibly argue better execution. And low chain penetration means independent clinics continue to set the default alternative in many cities. That combination implies that New Ruipeng’s competitive durability depends on standardization, doctor retention, referral conversion, and customer trust more than on category ownership. The company can win, but it has to prove that its larger ecosystem creates better economics and better care outcomes than the fragmented market or a leaner rival. Public-market comparators reinforce the same lesson: scale alone is not the moat investors reward; disciplined, repeatable economics are.[CP022, CP023, CP024, CP032, CP034, CP035]

3.5 Exhibits

4.1 Revenue model, mix, and growth quality

The filing shows a more diversified revenue engine than the label “pet hospital chain” suggests. In 2022 New Ruipeng generated RMB5.7402 billion of revenue, up 20.0% from 2021, with the increase driven primarily by supply chain services. Pet care services still formed the largest line at 51.7% of revenue, but supply chain rose to 38.0% and local services contributed 10.3%. This mix matters because it means the company’s financial model is not simply a clinic P&L multiplied across locations. It is a hybrid of medical fees, grooming, product distribution, local e-commerce, and prepayment-linked service flows. That hybrid cuts both ways. On one hand, it gives New Ruipeng more wallet-share surfaces than a pure hospital operator and may create cross-sell advantages once a customer enters the system. On the other hand, it makes quality-of-revenue analysis harder. A growing share from supply chain can lift scale faster than clinic throughput alone, but it may carry different gross-margin, working-capital, and cash-conversion characteristics than hospital care. Investors therefore need to separate “large revenue base” from “high-quality medical revenue base” when assessing the business.[CI001, CI006, CI007, CI008, CI009, CI010]

4.2 Unit economics proxies and cost structure

Public disclosure is rich enough to prove traction, but not rich enough to prove clinic-level economics. New Ruipeng disclosed roughly 2.6 million active pet-care customers in 2022, a repurchase rate of about 56%, average annual pet-care revenue per active customer of RMB1,129, and 5.2 million registered Rvet users. Those are useful signs that the customer base was real and that digital surfaces mattered. But the filing did not publish same-hospital sales, clinic contribution margin, payback period, or city-level profitability. That means the best available unit-economics view remains a proxy set rather than a full underwriting model. Cost structure is easier to diagnose. The company’s 2022 gross profit was RMB318.8 million on RMB5.7402 billion of revenue, implying gross margin of only about 5.6%. Net loss was RMB1.4171 billion and adjusted EBITDA was negative RMB948.2 million. Inventories of RMB680.3 million, property-and-equipment spending of RMB240.8 million, and continuing negative operating cash flow all reinforce the same conclusion: scale did not yet create obvious operating leverage by 2022. The business may still benefit from cross-sell and procurement over time, but publicly disclosed evidence shows a low-margin, asset- and working-capital-heavy operating model at the last audited checkpoint.[CI002, CI003, CI004, CI005, CI011, CI012]

4.3 Capital adequacy, financing dependence, and balance-sheet quality

The balance sheet was not distressed in the simple sense, but it was not self-funding either. At 2022 year-end the company had RMB566.8 million of cash and cash equivalents, RMB1.165 billion of restricted cash, and disclosed unused credit lines of RMB2.8564 billion, of which roughly RMB1.3952 billion was expected to be available for use. Short-term bank borrowings stood at RMB1.3838 billion. Read together, these numbers suggest a company that still had financing capacity, but not one that had escaped reliance on external capital or short-term borrowing. The funding timeline reinforces that view. The 2020 Tencent-led round and the January 2023 Nestlé convertible note both matter because the operating model appears to have required fresh capital to support network scale, working capital, and investment. The filing directly said equity financings and short-term bank borrowings had been the primary liquidity sources. That is a workable setup for a large private platform, but it also means the company’s capital adequacy cannot be judged purely from cash on hand. Investors have to ask how much of reported liquidity was truly discretionary, how much was tied up, and how much margin improvement would be needed before the business could finance growth internally.[CI015, CI016, CI017, CI018, CI023, CI031]

4.4 Financial verdict and diligence blockers

The financial verdict is mixed. New Ruipeng proved revenue scale, customer reach, diversified monetization, and continued access to capital. But the same public record also shows a company that entered 2023 with negative EBITDA, negative operating cash flow, heavy inventories, and dependence on financing. The June 2024 IPO withdrawal then sharply reduced transparency. While the company’s 2024 year-end message claimed the medical module turned profitable in March 2025, no audited 2024 or 2025 statements were found to test that claim. That makes the central diligence blocker current rather than historical. Historical data is enough to say the business was real and large. It is not enough to say whether the post-2024 organization has improved cash conversion, narrowed clinic-level losses, or achieved sustainable profitability. Public-comp comparisons from Chewy to Zoetis underscore the stakes: similar pet-adjacent revenue scale can map to very different market caps and multiples depending on margin structure and financial quality. Without current disclosures on segment margins, same-hospital trends, and cash burn, underwriting remains anchored to stale numbers.[CI024, CI025, CI026, CI034, CI035, CI036]

4.5 Exhibits

5.1 What the product actually is

New Ruipeng does not sell a single product in the software-company sense. Its public materials describe a care platform made up of more than 20 brands, 1,000-plus animal hospitals, 14 veterinary specialties, central and international hospitals, internet-hospital services, diagnostics, supply-chain enablement, and training systems. The filing reinforces that broader framing by listing third-party diagnosis, continued veterinary education, and marketing-as-a-service alongside core pet care. That breadth is strategically important because it means product quality depends on how well the company coordinates clinical, logistical, and digital assets rather than on one hero feature. The most tangible assets are the hospital network, the central diagnostics infrastructure, and the software systems that support care delivery. RVET and local-service surfaces extend the offering into consultation, booking, and aftercare. The international division extends the company into premium and specialist care formats, while the education layer supports clinician throughput and standardization. This is closer to a healthcare operating platform than a narrow chain-store retail concept.[CE001, CE005, CE007, CE009, CE011, CE013]

5.2 Operating architecture and customer workflow

The official product pages and filing make the operating architecture legible even without source code. At the base level, New Ruipeng says it built an ERP-centered business-process system spanning CRM, promotion management, supply chain, cashiering, reporting, and approvals. On the clinical side, the public pages point to HIS, CDSS, PACS, remote treatment, remote education, dog nose recognition, and digital medical records. The central lab adds pathology and molecular-diagnostics depth, while RVET handles pre-visit consultation, appointment flow, and post-visit interaction. Operationally, the 1+P+C model matters because it implies a referral architecture instead of flat store autonomy. Community hospitals handle high-frequency general-care traffic, specialty hospitals absorb more complex cases, and center hospitals concentrate difficult diagnosis, treatment, and rehabilitation. That structure can create better use of doctors and equipment if the digital stack and referral pathways work. It also makes software integration and standard workflows more important than they would be in a loose franchise or single-clinic model.[CE002, CE003, CE004, CE005, CE006, CE010]

5.3 Trust, quality controls, and differentiation

Public evidence suggests New Ruipeng is trying to compete on standardization and trust rather than on pure price. News detail 136 says the company led the first recommended national standard focused on pet diagnosis-and-treatment service institutions and had already rolled internal SOP manuals across 1,000-plus hospitals. The year-end letter highlights advanced equipment, specialty certifications, and AAHA-aligned quality recognition at a flagship hospital. Boehringer’s partnership framing adds another angle: New Ruipeng is presented as a channel for disease understanding, training, and higher-quality solutions at scale. Those signals support a differentiated quality story, but they are not complete proof of technical superiority. Public sources do not publish uptime, incident-rate, clinical-error, cyber-audit, or CDSS-adoption metrics. Most quality evidence is company-authored or partner-authored. That means the trust story is plausible and strategically coherent, yet still only partially auditable from outside.[CE008, CE016, CE017, CE018, CE019, CE020]

5.4 Roadmap, dependencies, and product verdict

The most forward-looking technical signal is VetMind, the AI ecosystem spun out through Xiaowen Technology and described by dvm360 in early 2026. Its publicly claimed modules — scribing, imaging, decision support, knowledge hub, microscopic assistant, and hospital assistant — align closely with the pain points one would expect inside a scaled veterinary network. If real, the 100-million-case training corpus and staged 2026-2027 rollout imply New Ruipeng is trying to export internal workflow know-how into a software layer. But because the dvm360 piece is sponsored and focused on North America, it is better read as evidence of technical direction than as conclusive proof of full deployment across China. The overall product verdict is therefore constructive with caveats. New Ruipeng clearly has a real operating stack, real diagnostics infrastructure, real referral design, and real standards work. Its dependencies are also substantial: clinicians, equipment, partner channels, software integration, data governance, and training all have to function simultaneously. The moat looks strongest where these layers reinforce one another; it looks weakest where public proof relies on self-description rather than externally auditable operating metrics.[CE012, CE021, CE022, CE023, CE024, CE026]

5.5 Exhibits

6.1 Customer segments and service surfaces

New Ruipeng is fundamentally a consumer healthcare company. Its buyers and payers are pet owners who purchase veterinary care, diagnostics, grooming, vaccination, boarding-adjacent services, and pet products for companion animals. The current official surfaces make that clear: the company markets a service menu that includes vaccinations, health examinations, parasite protection, teeth cleaning, spay/neuter procedures, remote diagnosis, online consultation, grooming, bathing, and SPA. The Ruipeng Pet Hospital consumer site reinforces the same point by advertising medical treatment together with grooming, boarding care, bathing, SPA, and food-and-supplies sales. This is not a narrow one-off surgery business; it is a recurring relationship business organized around the ongoing needs of pet parents. The current customer footprint is also multi-brand and multi-city. The official intro page says New Ruipeng operates more than 20 brands, more than 1,000 hospitals, and serves more than 90 cities, explicitly naming Beijing, Shanghai, Guangzhou, Shenzhen, Hong Kong, Chengdu, Hangzhou, Chongqing, Wuhan, Xi'an, Suzhou, Tianjin, Nanjing, Changsha, Zhengzhou, Shenyang, and Lanzhou. That footprint suggests a customer base centered on urban China, especially where higher-income pet ownership and specialty care are more established. The home page also says the company serves millions of pets and homeless animals in over 1,600 communities. Put together, the evidence supports a broad consumer funnel that starts with local discovery and extends through a layered network of central, specialty, international, and community hospitals.[CU001, CU002, CU003, CU004, CU005, CU006]

6.2 Historical adoption and usage proof

The strongest quantitative customer evidence still comes from the 2023 SEC filings. Those filings disclosed that active pet-care customers increased from about 2.5 million in 2021 to about 2.6 million in 2022, while annual net revenue per active customer fell modestly from RMB1,203 to RMB1,129. More importantly for durability, the company said it achieved an approximately 56% pet-care customer repurchase rate in 2022, versus an industry average of 30%-40%. For a veterinary chain, that is a meaningful sign that the network was not operating as a pure emergency-only service. It implies pet owners were coming back for repeat clinical and related services. The Rvet platform added a second adoption layer. The filings say Rvet had about 5.2 million registered users and about 1.347 million active customers in 2022, and explicitly define an active customer as a user making at least one purchase during the period. The same filing describes Rvet as a closed-loop online program and the company's core online platform for local services. It supports appointment booking, records review, expert consultation, monthly care packages, and product purchases. The filings also say roughly one-third of active hospital customers consumed in other company channels in 2022, suggesting that cross-sell between clinics and digital or retail surfaces was already material. Even though these numbers are stale, they remain the best public evidence that New Ruipeng had achieved real customer scale before returning to private-market opacity.[CU007, CU008, CU009, CU010, CU011, CU012]

6.3 Current channel proof and satisfaction signals

Current public evidence is thinner than the IPO-era filing but still shows live customer activity. News detail 133 says New Ruipeng deepened cooperation with Meituan's local-life platform and launched group-buy packages spanning vaccines, routine checkups, and disease-treatment services. That matters because it shows the company acquiring and merchandising demand through the same consumer platforms where many urban Chinese pet owners already search for local services. The same article reports that Meituan data showed improved repeat-purchase rates and satisfaction for New Ruipeng hospitals' local-life business, and that the group plus its affiliated hospitals won multiple awards including consumer-favorite merchant recognition and popularity-star-store awards. These are not audited NPS statistics, but they are still fresher customer signals than the 2022 filing. Broader consumer context also supports the relevance of New Ruipeng's market. The 2026 China Pet Industry White Paper says the urban dog-and-cat consumption market reached RMB312.6 billion in 2025, with medical care representing 27.6% of spending. It also shows that post-90s owners make up 42.7% of the market and post-00s another 26.3%, while hospital visits rose to 52.0% for dogs and 39.6% for cats. Those cohorts are digitally native and comfortable using local-service and app-based discovery. Rvet, JD-linked insurance settlement, and content/community surfaces like Kaisheng all fit that behavior pattern. The issue is not whether a customer market exists; it is whether New Ruipeng can convert broad traffic into durable, efficiently monetized repeat care as the sector matures.[CU016, CU017, CU018, CU019, CU021, CU022]

6.4 Retention quality and concentration verdict

The customer story is credible, but it is not fully underwritten. New Ruipeng has better public proof of breadth than of quality-adjusted durability. Historical filings show millions of users, meaningful repeat purchase, and cross-channel behavior. Current official pages still show a large urban brand network and active platform partnerships. Yet the company no longer publishes current active-customer counts, case volumes, retention cohorts, city-level conversion, or revenue concentration by channel. There is also no independent public roll-up of branch-level ratings because major Chinese review surfaces such as Dianping are difficult to access programmatically and were not reviewable in a stable fetched form during this run. The main downside signal is affordability pressure. 36Kr argues that many young Chinese pet owners are price-sensitive when facing higher-priced medical expenses and that smaller clinics still use price wars to attract customers. That matters because New Ruipeng is trying to sell standardized, higher-trust care through a scaled network that likely carries more overhead than a single independent clinic. The company's real concentration risk therefore looks less like one huge enterprise customer and more like a mix of urban concentration, channel dependence on local platforms and Rvet, and incomplete visibility into whether repeat usage translates into attractive city-level economics. The net verdict is constructive on customer breadth and ecosystem engagement, but cautious on current retention transparency and monetization quality.[CU024, CU025, CU027, CU028, CU030, CU031]

6.5 Exhibits

7.1 Regulatory and legal exposure

New Ruipeng operates in a tightly regulated corner of healthcare services. China's 2022 rules for animal diagnosis institutions require formal licenses, fixed premises, qualified staff, functional treatment areas, isolation controls, equipment, waste-handling systems, epidemic-reporting processes, and strict limits on practice scope. Branch expansion does not eliminate that burden; each branch institution must obtain its own license. The same rule set permits internet-enabled diagnosis activities only through filed-in veterinarians and only within the licensed scope of the institution. For a network that historically disclosed almost 1,900 hospitals and still markets itself as 1,000-plus hospitals today, that means the regulatory surface area scales with every site, every veterinarian, every record, and every online workflow. New Ruipeng's own filings show that this is not theoretical. The F-1/A says Rvet and Zhiyue already hold certain telecom licenses, yet additional permits may still be required for internet information, audio-visual, internet culture, online publishing, or private-school activities as interpretations evolve. The filing also warns that online local services and education activities may be deemed restricted or prohibited foreign-invested businesses under PRC law. Most importantly, the filing explicitly states that some hospitals used human or not-fully-approved veterinary drugs, some had inaccurate or incomplete drug records, and some did not follow all required procedures for narcotic and psychotropic drugs for animals. Those admissions turn compliance from a generic sector risk into a company-specific operating issue. New Ruipeng's leadership in national standards and internal SOP rollout is a real mitigation, but it is not an external clean bill of health.[CR001, CR002, CR003, CR004, CR005, CR006]

7.2 Operational, quality, and cybersecurity risk

The operational-risk stack goes well beyond licenses. The F-1/A warns that injuries to employees, customers, or trainees can create compensation, penalties, litigation, and reputational damage. It also warns that claims of improper animal care or poor communication can generate negative publicity that hurts revenue even when allegations are inaccurate. That is a meaningful risk for a brand positioning itself around health, wellness, digitization, and higher standards. In healthcare-style services, a scaled trust story cuts both ways: it creates differentiation when quality is consistent and magnifies damage when quality incidents spread across social media or local communities. Cyber and workflow risk are similarly material. New Ruipeng's filings and current product pages together show a network that depends on digital records, ERP, HIS, CDSS, PACS, remote diagnosis, online consultation, customer data, and partner-linked local-service flows. The filing says the company processes large amounts of customer and transaction data and that third-party service providers can access sensitive information. A breach or major outage would not merely be an IT inconvenience. It could trigger regulatory action, direct customer claims, insurance cost increases, and loss of trust at exactly the point where the company is trying to differentiate on integrated care. The public record also lacks any independent cybersecurity audit, penetration-test disclosure, or external reliability dashboard for these systems, so investors can see the digital ambition more clearly than the resilience evidence.[CR013, CR014, CR015, CR019, CR020, CR021]

7.3 Financial, governance, and partner risk

The financial and governance picture remains the hardest risk cluster to underwrite cleanly. The last audited public baseline is still 2022: RMB5.7402 billion of revenue, RMB318.8 million of gross profit, RMB1.4171 billion of net loss, and about negative RMB948.2 million of adjusted EBITDA. The June 2024 withdrawal proved that New Ruipeng could step back from public markets without ever pricing the offering, but it did not answer whether the company fixed the underlying profitability problem. Since then, the U.S. filing trail effectively ends. CapEdge and BamSEC show no new public operating update after the withdrawal request. OffshoreAlert headlines then introduced a new and more serious question: in November 2025, the Cayman parent reportedly sought the appointment of restructuring officers while still controlling more than 1,800 operating subsidiaries and branches in China. The detail is still too thin to model precisely, but it raises legitimate legal and financing uncertainty around the offshore holding structure. Partner and industry dependencies add another layer. JD can improve customer acquisition, insurance settlement, and at-home diagnostics, but it also creates dependency on non-owned channel execution and data-sharing arrangements. Boehringer brings training, disease understanding, and solution quality, yet some of the ecosystem story still leans on that strategic relationship. More broadly, 36Kr and other critical coverage argue that China's pet-medical market remains fragmented, price-sensitive, and structurally margin-constrained. If that framing is broadly right, then New Ruipeng carries not only company-specific risk but also business-model risk: the network may be operationally impressive and still struggle to convert scale into durable profits.[CR022, CR023, CR024, CR025, CR026, CR027]

7.4 Mitigations, monitoring indicators, and thesis-break triggers

There are real mitigants. New Ruipeng has scale, internal training infrastructure, thousands of licensed veterinarians in the last disclosed period, a structured 1+P+C referral model, digital workflow tools, national-standard leadership, and powerful strategic partners. These all lower the odds that a single local problem automatically becomes a systemic failure. But the residual risk stays high because the same company is trying to coordinate hospitals, veterinarians, supply chains, labs, customer data, internet services, education, and partner ecosystems while offering limited current public disclosure. In that configuration, risk transmission matters more than any single issue in isolation. The practical diligence stance is therefore to watch for hard triggers rather than broad optimism. The most important negative triggers would be any regulator-confirmed license or drug-compliance action across core hospitals; evidence that the Cayman restructuring process is expanding beyond a contained holding-company matter; continued absence of refreshed audited financials; visible same-store shrinkage or further hospital rationalization; or loss of key ecosystem partners such as JD or Boehringer. The positive offset would be publication of audited 2024 or 2025 numbers showing materially improved margins, plus transparent evidence that quality, licensing, data security, and staffing systems are holding up at scale. Until then, New Ruipeng looks less like a clean late-stage compounding asset and more like a large, strategically important operator with a meaningful residual-risk overhang.[CR010, CR023, CR025, CR029, CR030, CR032]

7.5 Exhibits

8.1 Recommendation, confidence, and entry discipline

The public evidence supports a real company, not a clean price-support story. New Ruipeng is not a speculative shell: it has real scale, a still-marketed 1,000-plus hospital network, meaningful historical revenue, real customers, and strategic relationships that are uncommon in Chinese pet healthcare. That is the core positive case. But public valuation underwriting is harsher. The only current company-specific price signal that is newer than the 2020 financing is a secondary Hurun-derived mark: RMB33 billion in 2025 and RMB30.5 billion in 2026. Hurun's own methodology makes clear that these list values are useful reference points, but they are not the same thing as a new priced financing or a cleared public-market trade. The last hard operating denominator is still 2022 revenue of RMB5.7402 billion from the F-1/A. On that denominator, the current Hurun-like mark implies about 5.3x-5.7x sales while the selected public comparables in this chapter mostly trade between about 0.7x and 4.0x. The exceptions are higher-quality animal-health names with cleaner margins and better disclosure. New Ruipeng also carries legal and structural overhangs that most public comps do not, including parent-level Cayman restructuring headlines and a much thinner public disclosure trail after the June 2024 IPO withdrawal. Recommendation: research-more rather than buy at the current reference mark. Confidence is medium because the company-quality case is real, but the price-support case still depends on non-public numbers. Risk rating is high because profitability, regulation, disclosure, and holding-company issues all matter to the multiple simultaneously. Entry discipline should be explicit: new money needs either a materially lower entry point — roughly the mid-to-high teens or low-20s billion RMB range — or fresh audited data proving a much stronger 2025-2026 financial profile than public evidence currently shows.[CV001, CV002, CV003, CV006, CV007, CV009]

8.2 Current valuation context and comparable set

The key valuation tension is straightforward. The 2020 round valued New Ruipeng at nearly RMB30 billion. A Baidu Baike page summarizing Hurun placements says the company later appeared at RMB33 billion in the 2025 Global Unicorn Index and RMB30.5 billion in the 2026 list. In other words, the public signal suggests that six years of scale-building, a U.S. listing attempt, and a later convertible note have produced little visible mark-up over the 2020 round. That is not necessarily bearish in itself — late-stage venture markets compressed sharply after 2021 — but it does mean investors cannot assume hidden compounding. The June 2024 RW withdrawal ended the public-listing path before a market-clearing price emerged, and CapEdge/BamSEC show that the public filing trail effectively stops there. The comparable set does not rescue the current mark. Yahoo Finance shows CVS Group at about 1.34x trailing sales and Pets at Home at about 0.67x. Chewy sits near 0.7x-0.8x on a market-cap-to-revenue lens depending on source and timing. Zoetis is the premium outlier at roughly 3.35x-4.05x because it is an animal-health pharmaceutical leader with much stronger margins, disclosure, and public-market depth than a clinic chain. Relative to that band, New Ruipeng's implied 5.3x-5.7x on stale 2022 revenue looks expensive. There is a path under which the mark becomes more reasonable: if 2025-2026 revenue has grown toward roughly RMB10-11 billion and margins have improved sharply, the same valuation signal would compress toward about 3x sales. But public evidence does not currently prove that. The weight of available evidence therefore says the current reference mark is a strategic-asset price, not a publicly supported fundamental price.[CV001, CV004, CV005, CV006, CV007, CV009]

8.3 Scenarios, ranges, and the price-support test

The scenario work makes the investment call more concrete. The bull case assumes New Ruipeng has quietly repaired more than public evidence shows: revenue scaled toward RMB10-12 billion, EBITDA turned positive, network rationalization improved unit economics rather than signaling distress, and the Cayman issue remains containable at the parent level. Under that set of assumptions, a roughly RMB28-34 billion valuation band becomes plausible. That is the only scenario that overlaps the current 2026 Hurun-like mark. The base case is less forgiving and better aligned with the public record. It assumes revenue nearer RMB8-9 billion, thinner margins than public bull arguments imply, and a market willing to pay about 2.0x-2.5x sales for a strategically important but still under-disclosed operator. That points to roughly RMB16-22 billion. The bear case is harsher: slower growth, continued EBITDA weakness, more visible store contraction, or deeper legal-structure stress could push value toward about RMB8-14 billion. That outcome would still recognize that New Ruipeng owns real scale and strategic relevance, but it would treat the business more like a complicated service-heavy network than a premium late-stage healthcare platform. The practical conclusion is that the current mark needs optimistic hidden data to clear; the public record alone supports downside skew rather than clear upside.[CV025, CV026, CV027, CV037, CV038, CV039]

8.4 Exit readiness, thesis-break triggers, and final diligence asks

Public evidence does not support an IPO-ready posture. A clean IPO-ready story would need current audited revenue quality, gross margin and EBITDA progression, cap-table and preference transparency, legal-structure clarity, and a much firmer answer to whether scaled pet-hospital operations in China can compound margins rather than merely compound footprint. Instead, the public record offers a withdrawn IPO, a sparse post-withdrawal disclosure trail, and a later OffshoreAlert headline about Cayman restructuring officers. That is enough to keep New Ruipeng investable as a tracking asset, but not enough to underwrite like a public-ready late-stage compounder. The final diligence list is therefore unusually explicit. Investors need audited 2024-2025 financials and a hospital-level margin bridge; the current cap table, liquidation preferences, and any creditor overhang; a verified store-count bridge and same-store operating trends; customer-retention and repeat-visit evidence; and compliance, cybersecurity, and clinical-quality audit outputs. Thesis-break triggers should likewise be explicit: any evidence of deeper Cayman stress, a new financing materially below current implied bands, further network contraction without visible margin repair, or confirmed regulatory or quality incidents across the core network. If those risks are contained and fresh numbers show that revenue and margins have inflected, the recommendation can move. Until then, the right posture is to respect the asset but price it cautiously.[CV016, CV031, CV033, CV044, CV045, CV046]

8.5 Exhibits